Ultragenyx Pharma (RARE) PT Raised to $90 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Ultragenyx Pharma (RARE) PT Raised to $59 at Morgan Stanley
August 7, 2018 7:14 AM EDTMorgan Stanley raised its price target on Ultragenyx Pharma (NASDAQ: RARE) to $59.00 (from $57.00) while maintaining a Equalweight rating.
... MoreUltragenyx Pharma (RARE) PT Raised to $80 at Wedbush
August 6, 2018 7:50 AM EDTWedbush raised its price target on Ultragenyx Pharma (NASDAQ: RARE) to $80.00 (from $71.00) while maintaining a Outperform rating.
... MoreUltragenyx Pharma (RARE) PT Raised to $85 at Piper Jaffray
August 3, 2018 6:01 AM EDTPiper Jaffray raised its price target on Ultragenyx Pharma (NASDAQ: RARE) to $85.00 (from $67.00) while maintaining a Overweight rating.
... MoreUltragenyx Pharma (RARE) PT Raised to $92 at Barclays
August 3, 2018 5:15 AM EDTBarclays raised its price target on Ultragenyx Pharma (NASDAQ: RARE) to $92.00 (from $74.00) while maintaining a Overweight rating.
... MoreUltragenyx Pharma (RARE) Posts Smaller-than-Expected Q2 Loss
August 2, 2018 5:06 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($1.06), $1.03 better than the analyst estimate of ($2.09). Revenue for the quarter came in at $12.8 million versus the consensus estimate of $5.42 million.
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
... More